Research theme for competitive and other funds (2)：
2022 - 2025 血液脳関門を介さない皮膚から脳への新規薬剤輸送機構の解明
2021 - 2024 Elucidation of the cause of phenotypic differences in tuberous sclerosis complex using model mice
Papers (11)：
Fumiki Yamashita, Makiko Koike-Kumagai, Manabu Fujimoto, Mari Wataya-Kaneda. Somatostatin-expressing inhibitory neurons with mTORC1 activation in cortical layers 4/5 are involved in the epileptogenesis of mice. Exploration of Neuroscience. 2024. 3. 6. 527-538
Makiko Koike-Kumagai, Manabu Fujimoto, Mari Wataya-Kaneda. Sex-based differences in neuropsychiatric symptoms are due to estradiol/ERα-dependent transcriptional regulation via the modulation of steroid levels by sirolimus. Pharmacology, biochemistry, and behavior. 2024. 173875-173875
Neuroinflammation and Microglial Polarity: Sirolimus Shifts Microglial Polarity to M2 phenotype in a Mouse Model of Tuberous Sclerosis Complex. Journal of Experimental Neurology. 2022. 3. 2
Makiko Koike-Kumagai, Manabu Fujimoto, Mari Wataya-Kaneda. Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice. Neuropharmacology. 2022. 218. 109203-109203
Brain estrogen levels are associated with gender differences in neuropsychiatric symptoms in mouse model of tuberous sclerosis complex, and sirolimus may contribute to symptom alleviation by controlling neurosteroid levels.
(The 2024 SID Annual Meeting,)
Epilepsy and TAND in the tuberous sclerosis complex are caused by an alteration in microglial polarity to M1 and sirolimus cures them by returning microglial polarity to M2.
(The 2023 International TSC Research Conference,)
Sirolimus alters microglial polarity leading to improvement of neuropsychiatric symptoms of tuberous sclerosis complex mice model.
(1 st. International Conference of Neuroscience and Neurology. Hybrid event in Dubai, UAE 2023)
